This analysis indicated that GOLPH3 protein expression level was positively associated with clinical stage (P < 0.001), and T (P < 0.001), N (P < 0.001), and M (P < 0.001) classification in patients with NSCLC (Fig. 1g). This evidence concerns the gene GOLPH3 and non-small cell lung carcinoma.